FDA Sticks Breakthrough Tag on GlaxoSmithKline's Blood Cancer Drug Post author:Sam Post published:November 1, 2017 Post category:BioPharma GSK2857916 is an anti B-cell maturation agent (BCMA) monoclonal antibody-drug conjugate. Source: BioSpace You Might Also Like Is There a Biotech Bubble Brewing in Boston? March 20, 2018 Stock Plummets as Genocea Axes 40% of Jobs, Shifts R&D Focus in Restructuring September 25, 2017 Sumitomo Dainippon Pharma, Poxel Ink $300M Diabetes Pact October 29, 2017
